ArticleMedicine2025
Causal association between circulating cytokine levels and the risk for asthma: A bidirectional, Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although some observational studies have linked circulating cytokine levels to asthma, their exact causal relationship(s) remain elusive. To address this knowledge gap, a Mendelian randomization (MR) study was performed to explore potential causal associations between circulating cytokine levels and asthma susceptibility using genetic instrumental variables. To investigate potential causal associations between circulating cytokines and asthma risk, a 2-sample MR analysis was performed using data from European participants from publicly available genome-wide association study summary statistics. Single nucleotide polymorphisms demonstrating significant associations with cytokine levels in previous studies were selected as instrumental genetic variables. A range of complementary MR approaches, including inverse variance weighted, weighted median, MR-Egger, weighted mode, simple mode, and MR pleiotropy residual sum and outlier (i.e., "MR-PRESSO") methods, were implemented to comprehensively investigate causality. Genetically predicted levels of the chemokines RANTES (regulated on activation, normal T-cell expressed and secreted [CCL5]), monocyte chemoattractant protein-1 (MCP-1), and growth-regulated protein alpha (GRO-α) exhibited significant causal associations with reduced asthma susceptibility, as evidenced by odds ratios (OR) of 0.935 (95% confidence interval [CI] 0.895-0.978; P = .003), 0.951 (95% CI 0.916-0.986; P = .007), and 0.968 (95% CI 0.944-0.992; P = .011), respectively. In contrast, beta-nerve growth factor (β-NGF; OR 1.043 [95% CI 1.000-1.087], P = .048), tumor necrosis factor-alpha (TNF-α; OR 1.040 [95% CI 1.001-1.081], P = .042), and macrophage colony stimulating factor (M-CSF; OR 1.032 [95% CI 1.001-1.064], P = .043) conferred increased causal risks for the development of asthma. These causal inferences remain robust across multiple complementary MR approaches, including MR-Egger, weighted median, weighted mode, and simple mode regressions. Sensitivity analyses excluded bias from horizontal pleiotropy. This MR analysis provides initial genomic evidence supporting genetically predicted causal relationships between circulating levels of RANTES, MCP-1, GRO-α, β-NGF, TNF-α, and M-CSF and altered susceptibility to asthma. These findings highlight the potential immunopathogenic roles of these cytokines in the onset and development of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.